C7A.02 Category · further specificity required Malignant carcinoid tumors of the appendix, large intestine, and rectum
ICD-10-CM C7A.02 identifies “Malignant carcinoid tumors of the appendix, large intestine, and rectum” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapter 2: Neoplasms
Code-level instructions
No additional notes.
Inherited instructions
C7A · Malignant neuroendocrine tumors
Use additional code2
- code to identify any associated endocrine syndrome, such as:
- carcinoid syndrome (E34.00)
Code also1
any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)
Chapters 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
More specific codes
C7A.020Malignant carcinoid tumor of the appendixBillable / specificC7A.021Malignant carcinoid tumor of the cecumBillable / specificC7A.022Malignant carcinoid tumor of the ascending colonBillable / specificC7A.023Malignant carcinoid tumor of the transverse colonBillable / specificC7A.024Malignant carcinoid tumor of the descending colonBillable / specificC7A.025Malignant carcinoid tumor of the sigmoid colonBillable / specificC7A.026Malignant carcinoid tumor of the rectumBillable / specificC7A.029Malignant carcinoid tumor of the large intestine, unspecified portionBillable / specificOfficial index references
References from other codes (3)
Excludes 1 · malignant carcinoid tumors of the colon (C7A.02-)
Excludes 1 · malignant carcinoid tumors of the colon (C7A.02-)
Excludes 2 · malignant carcinoid tumors of the colon (C7A.02-)
History
Code history
Latest recorded change · FY2025
Effective from
- Inherited rules changed
Malignant carcinoid tumors of the appendix, large intestine, and rectum
Category — select a more specific code
CDC/NCHS · FY2025All editions (19)
| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | No tabular change |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | No tabular change |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | No tabular change |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | Inherited rules changed |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.